Cantor Fitzgerald Estimates BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Bicara Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings of ($1.98) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $13.01 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28).

Several other equities analysts have also commented on BCAX. Wall Street Zen lowered shares of Bicara Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 price objective on the stock in a report on Friday, May 23rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Friday, May 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.86.

Bicara Therapeutics Stock Up 9.6%

Shares of BCAX stock opened at $12.58 on Tuesday. The firm’s 50-day moving average is $12.30 and its two-hundred day moving average is $14.03. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $28.09.

Institutional Trading of Bicara Therapeutics

Large investors have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in Bicara Therapeutics by 28.7% during the 4th quarter. Millennium Management LLC now owns 385,406 shares of the company’s stock worth $6,714,000 after purchasing an additional 85,847 shares during the period. Northern Trust Corp acquired a new stake in Bicara Therapeutics during the 4th quarter worth $2,771,000. Deutsche Bank AG acquired a new stake in Bicara Therapeutics during the 4th quarter worth $1,959,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics during the 4th quarter worth $33,000. Finally, Geode Capital Management LLC lifted its stake in shares of Bicara Therapeutics by 859.4% in the 4th quarter. Geode Capital Management LLC now owns 466,642 shares of the company’s stock worth $8,131,000 after acquiring an additional 418,003 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.